{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:13:23Z","timestamp":1783588403570,"version":"3.55.0"},"reference-count":34,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"unspecified","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Head and Neck Cancer Foundation Aotearoa","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["bmjph"],"accepted":{"date-parts":[[2026,3,30]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Prevalence of human papillomavirus (HPV)-related cancers in New Zealand (NZ) exceeds that of other high-income countries. These cancers are preventable by vaccination; however, NZ has a low and declining HPV vaccination rate. Literature on the economic burden of HPV-related cancers in NZ is limited. This study quantifies the economic burden of HPV-related cancers in NZ.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis of NZ patients with the six known HPV-associated cancers\u2014oropharyngeal, cervical, vaginal, vulvar, anus\/anal canal and penile cancers\u2014between 1 July 2017 and 30 June 2022 was performed. Total number of patients with these cancers, including non-HPV cases, was identified from the NZ Cancer Registry (NZCR). As HPV status is not recorded on the NZCR, the number of HPV-positive cases was estimated using data published by the Centre for Disease Control and Prevention (CDC). A prevalence cost-of-illness, non-discounted, approach was used to estimate the treatment cost of HPV-related cancers in the public health sector, with costs calculated using national data collections capturing outpatient, inpatient and pharmaceutical events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were an estimated 2342 cases of HPV-attributable cancers, with a cumulative treatment cost of NZ$82.4 million over a 4 year financial period, mostly incurred within the first 2 years of diagnosis. An additional $49 million was incurred for cervical pre-cancer detection by coloscopy and colposcopy-directed treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The cost of HPV-attributable cancers in NZ during 2019\u20132022 was conservatively estimated at NZ$131.4 million. This underestimates the true economic burden of the disease as it only includes treatment costs in the public health sector and the proportion of the HPV-associated cancers is based on CDC data. Despite the significant economic burden associated with HPV-related cancers, the vaccination rates in NZ are declining, highlighting the urgent need to increase the HPV vaccination rate to at least 90%, in line with the targets set by other developed countries. Further research evaluating the ethnic disparities and socioeconomic implications of HPV-related cancers is needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjph-2025-003800","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T18:05:15Z","timestamp":1778436315000},"page":"e003800","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Economic burden of human papillomavirus-related cancers in New Zealand"],"prefix":"10.1136","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2335-967X","authenticated-orcid":false,"given":"Sabrina P","family":"Koh","sequence":"first","affiliation":[{"name":"Wellington Regional Plastic, Maxillofacial and Burns Unit, Hutt Hospital, Lower Hutt, New Zealand"},{"name":"Gillies McIndoe Research Institute, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Stephenson","sequence":"additional","affiliation":[{"name":"Head and Neck Cancer Foundation Aotearoa, Wellington, New Zealand"},{"name":"Sexually Transmitted Infections Education Foundation, Welington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3796-5933","authenticated-orcid":false,"given":"John","family":"Chaplin","sequence":"additional","affiliation":[{"name":"Head and Neck Cancer Foundation Aotearoa, Wellington, New Zealand"},{"name":"Department of Otolaryngology, Auckland City Hospital, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Ruske","sequence":"additional","affiliation":[{"name":"Head and Neck Cancer Foundation Aotearoa, Wellington, New Zealand"},{"name":"Department of Otolaryngology, Dunedin Hospital, Dunedin, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1489-0182","authenticated-orcid":false,"given":"Andrew","family":"Macann","sequence":"additional","affiliation":[{"name":"Head and Neck Cancer Foundation Aotearoa, Wellington, New Zealand"},{"name":"Department of Oncology, University of Auckland, Auckland, New Zealand"},{"name":"Department of Radiation Oncology, Auckland City Hospital, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1727-3745","authenticated-orcid":false,"given":"Hayley","family":"Denison","sequence":"additional","affiliation":[{"name":"Sexually Transmitted Infections Education Foundation, Welington, New Zealand"},{"name":"Centre for Public Health Research, Massey University, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6772-719X","authenticated-orcid":false,"given":"Peter","family":"Sykes","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, University of Otago, Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Wellington Blood and Cancer Centre, Wellington Hospital, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Young","sequence":"additional","affiliation":[{"name":"Sapere Research Group, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Jenkinson","sequence":"additional","affiliation":[{"name":"Head and Neck Cancer Foundation Aotearoa, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0695-453X","authenticated-orcid":false,"given":"Swee T","family":"Tan","sequence":"additional","affiliation":[{"name":"Wellington Regional Plastic, Maxillofacial and Burns Unit, Hutt Hospital, Lower Hutt, New Zealand"},{"name":"Gillies McIndoe Research Institute, Wellington, New Zealand"},{"name":"Head and Neck Cancer Foundation Aotearoa, Wellington, New Zealand"},{"name":"Department of Surgery, The Royal Melbourne Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,10]]},"reference":[{"key":"2026070901202644000_4.2.e003800.1","unstructured":"World Health Organization . Cancer [online]. 2024. Available: https:\/\/www.who.int\/health-topics\/cancer [Accessed 23 Mar 2025]."},{"key":"2026070901202644000_4.2.e003800.2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/5315816","article-title":"New insights in the pathogenesis of HPV infection and the associated carcinogenic processes: the role of chronic inflammation and oxidative stress","volume":"2018","author":"Georgescu","year":"2018","journal-title":"J Immunol Res"},{"key":"2026070901202644000_4.2.e003800.3","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens12121380","article-title":"Epidemiology, molecular pathogenesis, immuno-pathogenesis, immune escape mechanisms and vaccine evaluation for HPV-associated carcinogenesis","volume":"12","author":"Jain","year":"2023","journal-title":"Pathogens"},{"key":"2026070901202644000_4.2.e003800.4","unstructured":"World Health Organization . Human papillomavirus vaccines: who position paper (2022 update) [online]. 2022. Available: https:\/\/www.who.int\/publications\/i\/item\/who-wer9750-645-672 [Accessed 23 Mar 2025]."},{"key":"2026070901202644000_4.2.e003800.5","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.biopha.2018.06.149","article-title":"The human papillomavirus (HPV)-related cancer biology: an overview","volume":"106","author":"Araldi","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"2026070901202644000_4.2.e003800.6","first-page":"80","article-title":"Review of HPV-related diseases and cancers","volume":"40","author":"Brianti","year":"2017","journal-title":"New Microbiol"},{"key":"2026070901202644000_4.2.e003800.7","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis","volume":"8","author":"de Martel","year":"2020","journal-title":"Lancet Glob Health"},{"key":"2026070901202644000_4.2.e003800.8","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30716"},{"key":"2026070901202644000_4.2.e003800.9","unstructured":"HPV Information Center . Human papillomavirus and related diseases report - New Zealand [online]. 2023. Available: https:\/\/hpvcentre.net\/statistics\/reports\/NZL.pdf [Accessed 27 Mar 2025]."},{"key":"2026070901202644000_4.2.e003800.10","unstructured":"HPV Information Center . Human papillomavirus and related diseases report - world [online]. 2023. Available: https:\/\/hpvcentre.net\/statistics\/reports\/XWX.pdf [Accessed 27 Mar 2025]."},{"key":"2026070901202644000_4.2.e003800.11","doi-asserted-by":"crossref","first-page":"102393","DOI":"10.1016\/j.canep.2023.102393","article-title":"Incidence, trends, and survival of oropharyngeal squamous cell cancer in Aotearoa New Zealand, 2006-2020","volume":"85","author":"Win Myint","year":"2023","journal-title":"Cancer Epidemiol"},{"key":"2026070901202644000_4.2.e003800.12","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.bjoms.2016.05.033","article-title":"Changing prevalence and treatment outcomes of patients with p16 human papillomavirus related oropharyngeal squamous cell carcinoma in New Zealand","volume":"54","author":"Kwon","year":"2016","journal-title":"Br J Oral Maxillofac Surg"},{"key":"2026070901202644000_4.2.e003800.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186424","article-title":"The prevalence of human papillomavirus in oropharyngeal cancer in a New Zealand population","volume":"12","author":"Lucas-Roxburgh","year":"2017","journal-title":"PLoS One"},{"key":"2026070901202644000_4.2.e003800.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2013.12.019"},{"key":"2026070901202644000_4.2.e003800.15","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-04-0551"},{"key":"2026070901202644000_4.2.e003800.16","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ygyno.2020.01.029","article-title":"Trends in HPV-dependent and HPV-independent vulvar cancers: the changing face of vulvar squamous cell carcinoma","volume":"157","author":"Eva","year":"2020","journal-title":"Gynecol Oncol"},{"key":"2026070901202644000_4.2.e003800.17","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ygyno.2018.10.045","article-title":"The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: transitional and long-term benefits, costs and resource utilisation implications","volume":"152","author":"Hall","year":"2019","journal-title":"Gynecol Oncol"},{"key":"2026070901202644000_4.2.e003800.18","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5596-2","article-title":"The healthcare costs of treating human papillomavirus-related cancers in Norway","volume":"19","author":"Hylin","year":"2019","journal-title":"BMC Cancer"},{"key":"2026070901202644000_4.2.e003800.19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179520","article-title":"The economic burden of human papillomavirus-related precancers and cancers in Sweden","volume":"12","author":"\u00d6stensson","year":"2017","journal-title":"PLoS One"},{"key":"2026070901202644000_4.2.e003800.20","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.1016\/j.vaccine.2011.05.018","article-title":"Economic burden of HPV-related cancers in France","volume":"29","author":"Borget","year":"2011","journal-title":"Vaccine (Auckl)"},{"key":"2026070901202644000_4.2.e003800.21","unstructured":"Centers for Disease Control and Prevention . Cancers linked with HPV each year [online]. 2025. Available: https:\/\/www.cdc.gov\/cancer\/hpv\/cases.html [Accessed 23 Mar 2025]."},{"key":"2026070901202644000_4.2.e003800.22","unstructured":"Statistics New Zealand . Infoshare - table reference CPI009AA [online]. 2025. Available: https:\/\/infoshare.stats.govt.nz [Accessed 23 Mar 2025]."},{"key":"2026070901202644000_4.2.e003800.23","unstructured":"Pharmac . Prescription for pharmacoeconomic analysis [online]. 2015. Available: https:\/\/www.pharmac.govt.nz\/assets\/pfpa-2-2.pdf [Accessed 17 Feb 2026]."},{"key":"2026070901202644000_4.2.e003800.24","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S2468-2667(16)30001-9","article-title":"Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models","volume":"1","author":"Brisson","year":"2016","journal-title":"Lancet Public Health"},{"key":"2026070901202644000_4.2.e003800.25","unstructured":"Health New Zealand . HPV immunisation programme [online]. 2024. Available: https:\/\/www.tewhatuora.govt.nz\/health-services-and-programmes\/vaccine-information\/hpv-immunisation-programme [Accessed 7 April 2025]."},{"key":"2026070901202644000_4.2.e003800.26","unstructured":"Data from gardasil 9 distributor csl seqirus, based on pharmac\u2019s records of vaccine shipments out of propharma. n.d."},{"key":"2026070901202644000_4.2.e003800.27","unstructured":"Cancer Society . HPV vaccination toolkit for health promoters and community advocates [online]. 2023. Available: https:\/\/www.cancer.org.nz\/about-us\/our-advocacy-work\/our-advocacy-campaigns\/hpv-vaccination-toolkit\/ [Accessed 7 April 2025]."},{"key":"2026070901202644000_4.2.e003800.28","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1080\/03036758.2025.2458028","article-title":"Realising the promise of HPV vaccination - data from the national cervical screening and vaccination registers demonstrates the impact of HPV vaccination in Aotearoa New Zealand","volume":"55","author":"Sykes","year":"2025","journal-title":"J R Soc N Z"},{"key":"2026070901202644000_4.2.e003800.29","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1016\/j.vaccine.2014.02.071","article-title":"Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand","volume":"32","author":"Blakely","year":"2014","journal-title":"Vaccine (Auckl)"},{"key":"2026070901202644000_4.2.e003800.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.12.017"},{"key":"2026070901202644000_4.2.e003800.31","doi-asserted-by":"crossref","first-page":"e1485","DOI":"10.1016\/S2214-109X(22)00306-0","article-title":"Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial","volume":"10","author":"Baisley","year":"2022","journal-title":"Lancet Glob Health"},{"key":"2026070901202644000_4.2.e003800.32","unstructured":"Cochrane Response . Efficacy, effectiveness and immunogenicity of one dose of HPV vaccine compared with no vaccination, two doses, or three doses [online]. 2022. Available: https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/position_paper_documents\/human-papillomavirus-(hpv)\/systematic-review-of-1-dose-of-hpv-vaccinec14d7ee3-e409-4a1a-afd9-c3e7e0dd2bd9.pdf?sfvrsn=174858f6_1 [Accessed 2 Aug 2025]."},{"key":"2026070901202644000_4.2.e003800.33","unstructured":"Health New Zealand . Clinical practice guidelines for cervical screening in Aotearoa New Zealand [online]. 2023. Available: https:\/\/www.tewhatuora.govt.nz\/assets\/Our-health-system\/Screening\/HPV-Primary-Screening\/clinical_practice_guidelines_final_version_1.1.pdf [Accessed 23 Mar 2025]."},{"key":"2026070901202644000_4.2.e003800.34","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462311000456"}],"container-title":["BMJ Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjph-2025-003800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T08:20:44Z","timestamp":1783585244000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjpublichealth.bmj.com\/lookup\/doi\/10.1136\/bmjph-2025-003800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,5,10]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/bmjph-2025-003800"],"URL":"https:\/\/doi.org\/10.1136\/bmjph-2025-003800","relation":{},"ISSN":["2753-4294"],"issn-type":[{"value":"2753-4294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}